KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Share-based Compensation (2016 - 2025)

Bio-Rad Laboratories has reported Share-based Compensation over the past 17 years, most recently at $15.9 million for Q4 2025.

  • Quarterly Share-based Compensation fell 3.05% to $15.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.8 million through Dec 2025, down 2.03% year-over-year, with the annual reading at $58.0 million for FY2025, 6.9% down from the prior year.
  • Share-based Compensation was $15.9 million for Q4 2025 at Bio-Rad Laboratories, up from $14.9 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $18.1 million in Q4 2022 and troughed at $11.4 million in Q2 2021.
  • The 5-year median for Share-based Compensation is $15.3 million (2021), against an average of $14.8 million.
  • Year-over-year, Share-based Compensation rose 29.55% in 2021 and then decreased 10.5% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $15.0 million in 2021, then increased by 20.67% to $18.1 million in 2022, then decreased by 10.5% to $16.2 million in 2023, then rose by 1.23% to $16.4 million in 2024, then fell by 3.05% to $15.9 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Share-based Compensation are $15.9 million (Q4 2025), $14.9 million (Q3 2025), and $16.4 million (Q4 2024).